Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

Add TROV Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/22/2017 10:06:21 AM - Followers: 44 - Board type: Free - Posts Today: 3

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.


Trovagene Closes Acquisition of CLIA Laboratory Assets
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board

Targeted $40 Billion market space:
TROV market space

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera® ctDNA Tests and Services in Cancer C... 08:00 AM
TROV News: Current Report Filing (8-k) 06/13/2017 04:22:07 PM
TROV News: Current Report Filing (8-k) 06/12/2017 04:02:24 PM
TROV News: Trovagene Enters Into Agreement with AstraZeneca to Utilize Trovera® ctDNA Test and Services in Prospective Biomarker Study 06/12/2017 08:00:00 AM
TROV News: Current Report Filing (8-k) 06/07/2017 05:02:15 PM
News News Alert: Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera® ctDNA Tests and Services in Cancer C... 06/22/2017 08:00:00 AM
#873   I know,Got a stop in 1,08 Gltu europtiger 06/22/17 10:06:21 AM
#872   Be Careful..... n3m3sis 06/22/17 09:49:15 AM
#871   In 1,23 europtiger 06/22/17 09:44:58 AM
#870   BUY ALERT -Chief Executive Officer, Bill Welch, will ice1234 06/13/17 01:09:47 PM
#869   * * $TROV Video Chart 06-06-17 * * ClayTrader 06/06/17 05:03:16 PM
#868   Okay a great green day$$$ JMO running bull 06/06/17 04:11:10 PM
#867   Had one of its best days in forever Tdash 04/13/17 03:38:11 PM
#866   So, no longer investment worthy, whats timing on ringao 04/12/17 06:44:03 AM
#865   I guess they are doing such a bang stockmule 04/11/17 09:17:43 AM
#864   wow ringao 04/11/17 06:49:30 AM
#863   Tough one to take, sold most right after ringao 03/23/17 07:31:45 AM
#862   On watch for bottom bouncer Klinsmann 03/22/17 10:25:22 AM
#861   Where Welch goes a trail of destruction follows, stockmule 03/20/17 06:05:57 PM
#860   This has gotten hammered. Great test maybe cash stockmule 03/09/17 11:20:38 AM
#859   I loaded up on TrovaGene on friday, under briphelps 01/21/17 08:25:01 AM
#858   Reorganization. Elimination of ~ 20 employees. $4M Optionsrbest4u 12/13/16 05:29:04 PM
#857   Dont say I didnt try to help. Whoever Tdash 12/08/16 12:31:06 PM
#856   hmmm. This $2.40 entry might be the start Tdash 12/08/16 10:25:32 AM
#855   I agree and I'm with ya. People don't ringao 12/02/16 04:22:41 PM
#854   Had to buy massive amount of shares of briphelps 12/01/16 05:20:39 PM
#853   I've been following it for sometime. What makes briphelps 08/18/16 09:04:19 AM
#852   Personally, think this is in the process of Pepsiman2001 08/17/16 06:31:42 PM
#851   Diagnostic Performance of Urinary EGFR Testing in Lung briphelps 07/26/16 09:27:39 AM
#850   Feller, undiscovered gem. briphelps 07/25/16 08:58:30 AM
#849 briphelps 07/25/16 08:57:55 AM
#848   I wonder if Bill Palaton is going to FELLER 07/18/16 01:00:57 PM
#847   LOL - Damn I got a good laugh crookedneck 06/30/16 02:40:24 PM
#846   That's funny, the whole market is bearish. Do briphelps 06/28/16 07:33:49 AM
#845   TROV bearish 4.24 stocktrademan 06/27/16 11:59:16 AM
#844   Liquid Biopsy Technology By William Patalon III, Executive briphelps 06/24/16 08:33:07 AM
#843   By James Altucher June 7, 2016 Why the briphelps 06/18/16 08:18:37 AM
#842   Haven't got a clue. Don't care either. $20 briphelps 06/18/16 08:13:26 AM
#841   Does he say approximately when it would go Wheatcrumb 06/17/16 08:29:31 AM
#840   Bill Patalon now promoting TrovaGene! briphelps 06/17/16 08:15:08 AM
#839   James Altucher new article about TroveGene! Worth $70 briphelps 06/15/16 09:46:15 AM
#838   One of my favor companies to watch. Have briphelps 06/01/16 08:35:39 PM
#837   Shelf Registration Expiration & Replacement apollo1452 05/30/16 09:28:09 PM
#836   Welch is a man who brings products to briphelps 05/24/16 08:57:50 AM
#835   Slapping The TROV Ask & Volume Increasing apollo1452 05/19/16 03:16:40 AM
#834   TROV is on my swing trade list. Latinachica 05/17/16 06:26:40 AM
#833   Similar Setup to Feb-March Run $3.51 to $6.93 apollo1452 05/17/16 02:13:51 AM
#832   TROV trading data confirms bullish reversal. apollo1452 05/06/16 04:07:31 AM
#831   Ouch, not looking very good. I think another stockmule 05/03/16 07:26:10 PM
#830   Welch got 750k share option at $4.73 when stockmule 05/02/16 09:42:55 AM
#829   I like TROV at these prices a lot. stockmule 04/28/16 09:14:21 AM
#828   He bought that stock up above $7 per briphelps 04/28/16 08:24:33 AM
#827   After the CEO announcement I think more like stockmule 04/25/16 07:31:17 PM
#826   * * $TROV Video Chart 04-25-16 * * ClayTrader 04/25/16 05:21:38 PM
#825   He exercised options to buy at 3.60 and nsomniyak 04/24/16 12:33:38 PM
#824   Looking very bullish and seems to be ready briphelps 04/24/16 10:29:15 AM